lactic acid has been researched along with Huntington Disease in 20 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (35.00) | 18.2507 |
2000's | 5 (25.00) | 29.6817 |
2010's | 8 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Solís-Maldonado, M | 1 |
Miró, MP | 1 |
Acuña, AI | 1 |
Covarrubias-Pinto, A | 1 |
Loaiza, A | 1 |
Mayorga, G | 1 |
Beltrán, FA | 1 |
Cepeda, C | 1 |
Levine, MS | 1 |
Concha, II | 1 |
Bátiz, LF | 1 |
Carrasco, MA | 1 |
Castro, MA | 1 |
Steventon, JJ | 1 |
Collett, J | 1 |
Furby, H | 1 |
Hamana, K | 1 |
Foster, C | 1 |
O'Callaghan, P | 1 |
Dennis, A | 1 |
Armstrong, R | 1 |
Németh, AH | 1 |
Rosser, AE | 1 |
Murphy, K | 1 |
Quinn, L | 1 |
Busse, M | 1 |
Dawes, H | 1 |
Joshi, AS | 2 |
Singh, V | 1 |
Gahane, A | 1 |
Thakur, AK | 2 |
Gouarné, C | 1 |
Tardif, G | 1 |
Tracz, J | 1 |
Latyszenok, V | 1 |
Michaud, M | 1 |
Clemens, LE | 1 |
Yu-Taeger, L | 1 |
Nguyen, HP | 1 |
Bordet, T | 1 |
Pruss, RM | 1 |
Tsang, TM | 1 |
Haselden, JN | 1 |
Holmes, E | 1 |
Duran, R | 1 |
Barrero, FJ | 1 |
Morales, B | 1 |
Luna, JD | 1 |
Ramirez, M | 1 |
Vives, F | 1 |
Josefsen, K | 1 |
Nielsen, SM | 1 |
Campos, A | 1 |
Seifert, T | 1 |
Hasholt, L | 1 |
Nielsen, JE | 1 |
Nørremølle, A | 1 |
Skotte, NH | 1 |
Secher, NH | 1 |
Quistorff, B | 1 |
Ciammola, A | 1 |
Sassone, J | 1 |
Sciacco, M | 1 |
Mencacci, NE | 1 |
Ripolone, M | 1 |
Bizzi, C | 1 |
Colciago, C | 1 |
Moggio, M | 1 |
Parati, G | 1 |
Silani, V | 1 |
Malfatto, G | 1 |
Ryu, JK | 1 |
Kim, SU | 1 |
McLarnon, JG | 1 |
Martin, WR | 1 |
Wieler, M | 1 |
Hanstock, CC | 1 |
Jenkins, BG | 4 |
Koroshetz, WJ | 3 |
Beal, MF | 4 |
Rosen, BR | 3 |
Brouillet, E | 1 |
Chen, YC | 2 |
Storey, E | 1 |
Schulz, JB | 1 |
Kirschner, P | 1 |
Harms, L | 1 |
Meierkord, H | 1 |
Timm, G | 1 |
Pfeiffer, L | 1 |
Ludolph, AC | 1 |
Rosas, HD | 2 |
Makabe, T | 1 |
Myers, R | 1 |
MacDonald, M | 1 |
Chen, YI | 1 |
Hayden, DL | 1 |
Cudkowicz, ME | 1 |
Gårseth, M | 1 |
Sonnewald, U | 1 |
White, LR | 1 |
Rød, M | 1 |
Zwart, JA | 1 |
Nygaard, O | 1 |
Aasly, J | 1 |
Gouhier, C | 1 |
Chalon, S | 1 |
Venier-Julienne, MC | 1 |
Bodard, S | 1 |
Benoit, J | 1 |
Besnard, J | 1 |
Guilloteau, D | 1 |
Cotton, P | 1 |
Barinaga, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881] | Phase 3 | 609 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 1.39 |
B - Placebo | 1.43 |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 4.29 |
B - Placebo | 5.06 |
"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -7.93 |
B - Placebo | -8.02 |
The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -26.30 |
B - Placebo | -24.86 |
Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -14.21 |
B - Placebo | -14.51 |
Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -7.57 |
B - Placebo | -8.61 |
Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -15.25 |
B - Placebo | -19.13 |
The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -10.95 |
B - Placebo | -11.36 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -4.53 |
B - Placebo | -4.76 |
The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 18.06 |
B - Placebo | 19.18 |
The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -5.07 |
B - Placebo | -4.47 |
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | rank (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 303.3 |
B - Placebo | 306.7 |
(NCT00608881)
Timeframe: 5 years
Intervention | participants completing study on drug (Number) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 98 |
B - Placebo | 108 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | days to event (Median) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 917 |
B - Placebo | 911 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | days to event (Median) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 553 |
B - Placebo | 549 |
1 trial available for lactic acid and Huntington Disease
Article | Year |
---|---|
Riluzole therapy in Huntington's disease (HD).
Topics: Adult; Basal Ganglia; Chorea; Excitatory Amino Acid Antagonists; Female; Humans; Huntington Disease; | 1999 |
19 other studies available for lactic acid and Huntington Disease
Article | Year |
---|---|
Altered lactate metabolism in Huntington's disease is dependent on GLUT3 expression.
Topics: Animals; Cell Line; Corpus Striatum; Disease Models, Animal; Female; Glucose Transporter Type 3; Hum | 2018 |
Alterations in the metabolic and cardiorespiratory response to exercise in Huntington's Disease.
Topics: Adult; Aged; Exercise; Female; Heart Rate; Humans; Huntington Disease; Lactic Acid; Male; Middle Age | 2018 |
Biodegradable Nanoparticles Containing Mechanism Based Peptide Inhibitors Reduce Polyglutamine Aggregation in Cell Models and Alleviate Motor Symptoms in a Drosophila Model of Huntington's Disease.
Topics: Animals; Blood-Brain Barrier; Brain; Cell Aggregation; Disease Models, Animal; Drosophila; Huntingto | 2019 |
Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease.
Topics: Animals; Cell Respiration; Corpus Striatum; Disease Models, Animal; Extracellular Space; Glucose; Gl | 2013 |
Biodegradable delivery system containing a peptide inhibitor of polyglutamine aggregation: a step toward therapeutic development in Huntington's disease.
Topics: Blood-Brain Barrier; Humans; Huntingtin Protein; Huntington Disease; Lactic Acid; Nanoparticles; Ner | 2014 |
Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Choline; Corpus Striatum; | 2009 |
Oxidative stress and plasma aminopeptidase activity in Huntington's disease.
Topics: Adult; Aminopeptidases; Female; Heterozygote; Humans; Huntington Disease; Lactic Acid; Lipid Peroxid | 2010 |
Reduced gluconeogenesis and lactate clearance in Huntington's disease.
Topics: Animals; Blood Glucose; Blotting, Western; Brain; Exercise; Exercise Test; Female; Gluconeogenesis; | 2010 |
Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease.
Topics: Adult; Aged; Anaerobic Threshold; Analysis of Variance; Cells, Cultured; Female; Heart; Humans; Hunt | 2011 |
Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Drug Administration Routes; Enzyme Inhibitors; Guanidines; Huntingt | 2004 |
Is brain lactate increased in Huntington's disease?
Topics: Adult; Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Female; Humans; Huntington Dis | 2007 |
Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy.
Topics: Adult; Aspartic Acid; Basal Ganglia; Choline; Creatine; Energy Metabolism; Female; Humans; Huntingto | 1993 |
Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging.
Topics: Aging; Animals; Aspartic Acid; Electron Transport Complex II; Energy Metabolism; Huntington Disease; | 1996 |
Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Aspartic Acid; Choline; Female; Frontal Lobe; Humans; Huntington Disease; Lactic Acid; | 1997 |
1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.
Topics: Adult; Brain; Case-Control Studies; Corpus Striatum; Energy Metabolism; Female; Humans; Huntington D | 1998 |
Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease.
Topics: Adult; Aged; Citric Acid; Energy Metabolism; Female; Humans; Huntington Disease; Lactic Acid; Magnet | 2000 |
Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide.
Topics: Animals; Antineoplastic Agents; Autoradiography; Benzamides; Biocompatible Materials; Corpus Striatu | 2000 |
Neuroscientists begin to piece together more parts of Huntington's disease puzzle.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biomarkers; Brain Chemistry; Dise | 1992 |
Neuroscience fantasia in an appropriate setting.
Topics: Cilia; Hair Cells, Auditory; Hearing; Humans; Huntington Disease; Lactates; Lactic Acid; Neuroscienc | 1992 |